Adaptogens and the Stress Response: Clinical Evidence for HPA Axis Modulation

The term adaptogen entered scientific discourse in 1947 when Soviet toxicologist Nikolai Lazarev defined it as a substance that increases nonspecific resistance to stress. Six decades of research have since refined this definition and mapped the biochemical pathways through which these compounds influence human stress physiology. Unlike acute pharmacological interventions, adaptogens appear to operate through bidirectional modulation of the hypothalamic-pituitary-adrenal axis and related signaling cascades.

Modern clinical interest centers on whether these botanical compounds can meaningfully alter stress biomarkers in controlled settings, and if so, through what mechanisms. The evidence base now includes randomized controlled trials measuring cortisol dynamics, sympathoadrenal activity, and downstream markers of cellular stress adaptation. This brief examines the clinical data on adaptogen-mediated stress response modulation, with emphasis on documented mechanisms and population-specific considerations.

What Are Adaptogens?

Adaptogens represent a pharmacological class of plant-derived compounds that meet three criteria established by Brekhman and Dardymov in 1969: they must be non-toxic at normal doses, produce a nonspecific increase in resistance to diverse stressors, and normalize physiological function regardless of the direction of pathological change. This last criterion distinguishes adaptogens from conventional stimulants or sedatives, which shift function in a single direction.

The most extensively studied adaptogens include Rhodiola rosea, Withania somnifera (ashwagandha), Eleutherococcus senticosus (Siberian ginseng), Schisandra chinensis, and Panax ginseng. Each contains multiple bioactive constituents rather than a single active compound. In Rhodiola, salidroside and rosavins are considered primary markers; in ashwagandha, withanolide glycosides predominate. This biochemical complexity makes mechanistic research challenging but may contribute to the multi-target effects observed clinically.

Contemporary adaptogen research focuses on interaction points between botanical compounds and mammalian stress response systems, particularly the HPA axis, heat shock protein expression, nitric oxide pathways, and cortisol receptor sensitivity. The clinical question is whether these interactions translate to measurable changes in stress biomarkers and subjective stress perception in human subjects.

What Are Adaptogens Used For in Clinical Contexts?

Clinical applications of adaptogens center on conditions where HPA axis dysregulation or chronic stress exposure plays a documented role. The evidence base supports several specific use cases, though effect sizes and study quality vary considerably across indications.

• Chronic stress and burnout: Multiple RCTs have tested adaptogens in populations with elevated perceived stress scores, using validated instruments like the Perceived Stress Scale (PSS) and measuring cortisol awakening response as an objective endpoint [1][2]
• Fatigue and physical performance: Studies in athletes and military personnel have examined effects on exhaustion thresholds, VO2 max, and recovery biomarkers following standardized exercise protocols [3]
• Cognitive function under stress: Trials measuring attention, working memory, and processing speed during acute stress exposure or chronic stress states [4]
• Anxiety symptoms: Several adaptogens have been tested against clinical anxiety scales, particularly in generalized anxiety disorder and stress-related anxiety presentations [5]
• Sleep quality: Secondary endpoints in stress trials often include sleep latency and architecture, given the bidirectional relationship between HPA axis function and circadian regulation

The clinical rationale rests on adaptogen effects occurring upstream of multiple symptom domains. Rather than targeting a single neurotransmitter or receptor system, these compounds may influence the set-point and responsiveness of central stress integration systems, potentially explaining the diverse endpoints reported across trials.

Evidence and Mechanisms: HPA Axis Modulation

The hypothalamic-pituitary-adrenal axis represents the primary endocrine pathway coordinating mammalian stress responses. When the brain perceives a stressor, the paraventricular nucleus of the hypothalamus secretes corticotropin-releasing hormone, triggering pituitary ACTH release and subsequent adrenal cortisol secretion. Chronic activation of this cascade is associated with immune suppression, metabolic dysfunction, and hippocampal damage. Adaptogens appear to modulate this system at multiple nodes.

A 2019 systematic review of ashwagandha trials identified five RCTs measuring serum cortisol as a primary or secondary endpoint [1]. Pooled analysis showed a mean reduction of 14.3% in morning cortisol levels compared to placebo (95% CI: -23.1% to -5.5%, p=0.002). The effect was most pronounced in individuals with baseline cortisol levels in the upper tertile of the reference range, suggesting a normalizing rather than universally suppressive effect. One eight-week trial using 600mg daily of standardized ashwagandha root extract reported a 27.9% reduction in serum cortisol alongside significant improvements in PSS scores [2]. Importantly, cortisol reduction correlated with subjective stress improvement (r=0.56, p<0.001), supporting cortisol as a mechanistically relevant biomarker rather than an epiphenomenon.

In a 60-day RCT of 101 adults with chronic stress, 300mg twice-daily ashwagandha extract reduced serum cortisol by 27.9% compared to 7.9% in placebo (p<0.001), while Perceived Stress Scale scores declined by 44.0% versus 5.5% (p<0.001).

Rhodiola rosea demonstrates a distinct mechanistic profile. A 2012 trial in 101 subjects with life-stress symptoms used 200mg twice-daily of a standardized extract (3% rosavins, 1% salidroside) for four weeks [3]. While serum cortisol showed no significant change, salivary cortisol awakening response was significantly blunted (area under curve reduced 18.3%, p=0.031), and self-reported burnout scores declined 31% on the Pines Burnout Scale. This dissociation between serum and salivary cortisol, along with preserved circadian amplitude, suggests Rhodiola may modulate cortisol receptor sensitivity or local tissue metabolism rather than total cortisol production. For readers interested in the specific clinical data on cortisol dynamics, our analysis of ashwagandha and cortisol trials provides detailed effect sizes across populations.

At the molecular level, adaptogens influence stress-activated protein kinase pathways, particularly the SAPK/JNK cascade involved in cellular stress signaling [6]. In vitro models show that ashwagandha withanolides inhibit stress-induced phosphorylation of c-Jun N-terminal kinase, reducing downstream inflammatory cytokine expression. Rhodiola constituents upregulate expression of heat shock proteins HSP70 and HSP90, molecular chaperones that protect cellular proteins during metabolic stress. A 2009 study in isolated neurons found that salidroside prevented glutamate-induced apoptosis through activation of PI3K/Akt survival signaling [7]. Whether these cellular mechanisms fully explain the clinical effects on perceived stress and cortisol dynamics remains an area of active investigation.

The concept of hormesis provides an additional framework for understanding adaptogen action. By inducing mild cellular stress, these compounds may activate endogenous defense systems that subsequently provide protection against more severe stressors. This mechanism parallels the effects of exercise and caloric restriction, where controlled stress exposure confers adaptive benefits. The threshold between hormetic benefit and actual toxicity depends on dose, duration, and individual physiological reserve, which explains both the clinical variability in response and the importance of standardized extracts.

Clinical Considerations Across Populations

Baseline Stress State and Responsiveness

The magnitude of adaptogen effects correlates strongly with baseline stress burden. A meta-regression of 11 Rhodiola trials found that effect size on fatigue measures increased linearly with baseline stress scores (β=0.42, p=0.009) [8]. Subjects with PSS scores below 14 showed minimal benefit, while those scoring above 20 demonstrated clinically meaningful reductions. This pattern aligns with the normalization concept central to adaptogen definition: these compounds appear most effective when homeostatic systems are already displaced from optimal function.

• Individuals with diagnosed burnout or chronic stress syndromes show the most consistent responses across multiple outcome measures
• Healthy volunteers under experimentally induced acute stress show more variable results, likely due to intact compensatory mechanisms
• The cortisol-lowering effect of ashwagandha is most pronounced in subjects with baseline morning cortisol above 15 μg/dL [1]

Duration of Treatment and Onset Kinetics

Adaptogen effects on stress biomarkers follow a distinct time course. Subjective improvements in perceived stress and sleep quality often emerge within 1-2 weeks, while objective changes in cortisol patterns typically require 4-8 weeks of consistent supplementation [2][3]. This delayed objective response may reflect the time required for receptor modulation and transcriptional changes in HPA axis tissues.

• Early improvements (1-2 weeks): subjective stress, sleep latency, mental fatigue
• Intermediate changes (4-6 weeks): cortisol awakening response, inflammatory markers
• Late-emerging effects (8-12 weeks): cognitive performance, metabolic parameters

Trial durations shorter than four weeks should be interpreted cautiously, as they may capture only the earliest phase of adaptation. Conversely, long-term studies (beyond 12 weeks) are scarce, leaving questions about sustained efficacy and potential tolerance development unanswered.

Interactions with Concurrent Medications

The biochemical activity that makes adaptogens useful also creates potential for drug interactions. Ashwagandha enhances GABA-A receptor signaling and may potentiate sedative medications, benzodiazepines, and other CNS depressants [9]. Rhodiola shows monoamine oxidase inhibition in preclinical models, raising theoretical concerns with SSRIs and MAOIs, though clinical interaction reports are rare.

• Thyroid medication: ashwagandha may increase T4 production; monitor TSH in hypothyroid patients
• Immunosuppressants: theoretical antagonism with compounds that enhance immune function
• Diabetes medications: potential additive glucose-lowering effects require monitoring
• Blood pressure medications: adaptogen effects on sympathetic tone may alter antihypertensive efficacy

Current evidence does not support absolute contraindications for adaptogens in most medicated populations, but initiation under clinical supervision with appropriate monitoring is prudent, particularly when multiple medications are involved.

Pregnancy, Lactation, and Pediatric Use

Safety data in pregnancy and lactation are limited for most adaptogens. Ashwagandha has traditionally been avoided in pregnancy due to potential uterotonic effects, though human data are sparse [10]. No published trials have examined adaptogen safety or efficacy in children under 12 years. Until such data emerge, use in these populations should be considered investigational.

How to Choose an Adaptogen-Based Supplement

• Standardized extract concentration: Select products listing specific marker compounds with percentages. For ashwagandha, KSM-66 (standardized to ≥5% withanolides) and Sensoril (10% withanolides) have the most clinical support. Rhodiola should specify both rosavins (typically 3%) and salidroside (1%).
• Dosing alignment with clinical data: Effective doses in RCTs are typically 300-600 mg/day for ashwagandha and 200-400 mg/day for Rhodiola. Products using proprietary blends without disclosed individual compound doses make efficacy assessment impossible.
• Multi-pathway formulation: Single-ingredient supplements may miss complementary mechanisms. Look for formulations combining HPA-axis modulators (ashwagandha) with neurotransmitter precursors (L-tyrosine), acetylcholine support (alpha-GPC), and agents that buffer sympathetic activation (L-theanine).
• Absence of stimulant over-reliance: While caffeine can provide acute cognitive support, doses above 100mg may counteract adaptogen effects on sympathetic tone. Formulations pairing adaptogens with moderate caffeine (50-75mg) and L-theanine show better stress biomarker profiles than high-caffeine alternatives.
• Third-party testing and purity verification: Botanical supplements face contamination risks including heavy metals and microbial pathogens. Certificates of analysis from independent labs provide necessary quality assurance beyond manufacturer claims.

Conclusion

The clinical evidence supports adaptogens as modulators of HPA axis function and stress biomarkers, with the strongest data for ashwagandha and Rhodiola rosea. Effect sizes are most pronounced in populations with elevated baseline stress, suggesting these compounds facilitate normalization rather than producing universal physiological shifts. Mechanisms involve cortisol regulation, neuroprotective signaling, and cellular stress response activation, though the relative contribution of each pathway likely varies by compound and context.

The translation of these effects to real-world stress management depends on appropriate dosing, sufficient treatment duration, and integration with other evidence-based stress interventions. Formulations combining standardized ashwagandha extracts with neurotransmitter support, phospholipids for neuronal membrane integrity, and balanced stimulation offer a biochemically coherent approach to supporting the stress response system. As with any intervention targeting complex neuroendocrine function, individual response variability is substantial, and monitoring of subjective symptoms alongside objective markers when feasible provides the clearest picture of clinical utility.